Equities Analysts Offer Predictions for argenx SE -‘s FY2018 Earnings (ARGX)
argenx SE – (NASDAQ:ARGX) – Analysts at Wedbush upped their FY2018 EPS estimates for argenx in a research note issued on Tuesday, December 4th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($1.91) for the year, up from their prior forecast of ($2.25). Wedbush has a “Outperform” rating and a $131.00 price objective on the stock. Wedbush also issued estimates for argenx’s Q4 2018 earnings at ($0.82) EPS, FY2019 earnings at ($2.94) EPS, FY2020 earnings at ($5.15) EPS, FY2021 earnings at ($4.66) EPS and FY2022 earnings at $5.54 EPS.
Other research analysts have also issued reports about the company. Evercore ISI began coverage on argenx in a research report on Monday, October 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Piper Jaffray Companies reaffirmed an “overweight” rating and issued a $154.00 target price on shares of argenx in a research report on Monday, September 17th. SunTrust Banks increased their target price on argenx to $132.00 and gave the stock an “in-line” rating in a research report on Tuesday, September 18th. JMP Securities increased their target price on argenx to $150.00 and gave the stock an “outperform” rating in a research report on Monday, September 17th. Finally, Zacks Investment Research raised argenx from a “hold” rating to a “buy” rating and set a $104.00 target price on the stock in a research report on Monday, November 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $136.00.
Several institutional investors and hedge funds have recently modified their holdings of the stock. Northern Trust Corp raised its position in shares of argenx by 11.5% in the 2nd quarter. Northern Trust Corp now owns 12,418 shares of the company’s stock worth $1,029,000 after buying an additional 1,285 shares during the period. Dimensional Fund Advisors LP raised its position in argenx by 22.1% in the second quarter. Dimensional Fund Advisors LP now owns 7,559 shares of the company’s stock valued at $626,000 after purchasing an additional 1,366 shares during the period. Capital Fund Management S.A. purchased a new position in argenx in the third quarter valued at about $212,000. Stevens Capital Management LP purchased a new position in argenx in the third quarter valued at about $214,000. Finally, TD Asset Management Inc. raised its position in argenx by 8.2% in the second quarter. TD Asset Management Inc. now owns 38,832 shares of the company’s stock valued at $3,218,000 after purchasing an additional 2,952 shares during the period. 64.40% of the stock is currently owned by institutional investors and hedge funds.
argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.
See Also: Float
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.